Protara Therapeutics (TARA) Research & Development (2013 - 2026)

Protara Therapeutics (TARA) has reported Research & Development for 14 consecutive years, with $13.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Research & Development rose 48.25% year-over-year to $13.6 million; the TTM figure through Mar 2026 stood at $47.0 million (up 42.12% YoY), while the FY2025 annual figure was $42.6 million, up 34.47% from the prior year.
• Research & Development climbed to $13.6 million in Q1 2026 per TARA's latest filing, from $13.1 million in the prior quarter.
• Across five years, Research & Development topped out at $13.6 million in Q1 2026 and bottomed at $3.1 million in Q2 2022.
• Historically, Research & Development has averaged $7.6 million across 5 years, with a median of $7.2 million in 2023.
• Annual changes were most pronounced in 2022 — Research & Development tumbled 47.61% — and 2023, when it jumped 134.99%.
• Protara Therapeutics' Research & Development stood at $5.0 million in 2022, then rose by 27.9% to $6.4 million in 2023, then jumped by 48.86% to $9.5 million in 2024, then soared by 38.16% to $13.1 million in 2025, then advanced by 3.34% to $13.6 million in 2026.
• Business Quant data shows TARA's Research & Development at $13.6 million in Q1 2026, $13.1 million in Q4 2025, and $9.6 million in Q3 2025.